ID   SNB-78
AC   CVCL_B321
SY   SNB78; Surgical Neurology Branch-78
DR   ChEMBL-Cells; CHEMBL3307969
DR   ChEMBL-Targets; CHEMBL612543
DR   Cosmic; 1436043
DR   IARC_TP53; 21646
DR   PubChem_Cell_line; CVCL_B321
DR   Wikidata; Q54955043
RX   DOI=10.1016/B978-0-12-333530-2.50005-8;
RX   PubMed=2041050;
RX   PubMed=3121170;
RX   PubMed=15900046;
RX   PubMed=22336246;
CC   Part of: JFCR39 cancer cell line panel.
CC   Doubling time: 50 +- 2 hours (PubMed=3121170).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro223Ala (c.667C>G); Zygosity=Unspecified (PubMed=15900046).
CC   Derived from site: In situ; Brain; UBERON=UBERON_0000955.
DI   NCIt; C3058; Glioblastoma
DI   ORDO; Orphanet_360; Glioblastoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   71Y
CA   Cancer cell line
DT   Created: 06-06-12; Last updated: 29-06-23; Version: 21
RX   DOI=10.1016/B978-0-12-333530-2.50005-8;
RA   Nister M., Westermark B.;
RT   "Human glioma cell lines.";
RL   (In) Atlas of human tumor cell lines; Hay R.J., Park J.-G., Gazdar A.F. (eds.); pp.17-42; Academic Press; New York (1994).
RX   PubMed=2041050; DOI=10.1093/jnci/83.11.757;
RA   Monks A., Scudiero D.A., Skehan P., Shoemaker R.H., Paull K.D.,
RA   Vistica D.T., Hose C.D., Langley J., Cronise P., Vaigro-Wolff A.,
RA   Gray-Goodrich M., Campbell H., Mayo J.G., Boyd M.R.;
RT   "Feasibility of a high-flux anticancer drug screen using a diverse
RT   panel of cultured human tumor cell lines.";
RL   J. Natl. Cancer Inst. 83:757-766(1991).
RX   PubMed=3121170;
RA   Gross J.L., Behrens D.L., Mullins D.E., Kornblith P.L., Dexter D.L.;
RT   "Plasminogen activator and inhibitor activity in human glioma cells
RT   and modulation by sodium butyrate.";
RL   Cancer Res. 48:291-296(1988).
RX   PubMed=15900046; DOI=10.1093/jnci/dji133;
RA   Mashima T., Oh-hara T., Sato S., Mochizuki M., Sugimoto Y.,
RA   Yamazaki K., Hamada J.-i., Tada M., Moriuchi T., Ishikawa Y., Kato Y.,
RA   Tomoda H., Yamori T., Tsuruo T.;
RT   "p53-defective tumors with a functional apoptosome-mediated pathway: a
RT   new therapeutic target.";
RL   J. Natl. Cancer Inst. 97:765-777(2005).
RX   PubMed=22336246; DOI=10.1016/j.bmc.2012.01.017;
RA   Kong D.-X., Yamori T.;
RT   "JFCR39, a panel of 39 human cancer cell lines, and its application in
RT   the discovery and development of anticancer drugs.";
RL   Bioorg. Med. Chem. 20:1947-1951(2012).